Taysha Gene Therapies is trading 6.05% higher at $4.38 in pre-market, with no confirmed company announcement explaining the move.
- The Nasdaq is up 0.81% and the Dow is up 0.54%, which may be contributing to the gain.
- An article about an Astellas investment is dated October 25, 2022, not a new 2026 catalyst.
- The company is expected to report Q3 results on November 3; that upcoming report does not establish the cause of the gain.